Streetbeat News

XCUR

Exicure, Inc.

https://www.exicuretx.com

Industry

Biotechnology

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Open

4.27

Mkt cap

12M

Volume

High

5.53

P/E Ratio

-1.23

52-wk high

6.00

Low

4.26

Div yield

N/A

52-wk low

1.44

The article highlights significant intraday movements in healthcare stocks, with Biofrontera, Autonomix Medical, Anavex Life Sciences, Aerovate Therapeutics, MiMedx Group, and Exicure seeing gains, while Matinas BioPharma, Anika Therapeutics, Psyence Biomedical, CalciMedica, Compass Pathways, and Vaccinex experienced losses.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 4:34 pm

The article highlights significant intraday movements in healthcare stocks, with NewGenIvf Group, Gritstone Bio, and Vicarious Surgical among the top gainers, while Seelos Therapeutics and Mainz Biomed are notable losers.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 4:32 pm

Exicure shares experienced a trading halt due to a circuit breaker triggered by a downside move, but the stock has since rebounded and is now up by 6.59%.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 3:35 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. Notable gainers include Carmell (CTCX), Clearside Biomedical (CLSD), and Kezar Life Sciences (KZR), while Nexalin Technology (NXL) and Tivic Health Systems (TIVC) were among the losers.

Portfolio Pulse from Benzinga Insights

October 09, 2024 | 12:07 pm

In Tuesday's after-market session, several healthcare stocks experienced significant price movements. Kezar Life Sciences (KZR) led the gainers with a 28.2% increase, while Nexalin Technology (NXL) saw the largest decline, dropping 14.7%.

Portfolio Pulse from Benzinga Insights

October 08, 2024 | 8:31 pm

Nike shares surged 7% in pre-market trading following the announcement of Elliott Hill as the new CEO. Other stocks also showed significant pre-market movements, including Banzai International, Battalion Oil, and FedEx, which reported weaker-than-expected results.

Portfolio Pulse from Avi Kapoor

September 20, 2024 | 10:00 am

On September 19th, significant market movements were observed for Galmed Pharmaceuticals, Edgewise Therapeutics, and Exicure. Galmed plans to expand its drug development with two new programs. Edgewise reported top-line data from its trials, and Exicure received a Nasdaq extension.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 12:06 pm

Exicure, Inc. (NASDAQ:XCUR) shares surged 179.9% in pre-market trading after receiving a Nasdaq listing extension. Other notable pre-market movers include Zeo Energy Corp. (NASDAQ:ZEO) up 288.9%, Telesis Bio, Inc. (NASDAQ:TBIO) up 138.4%, and Venus Concept Inc. (NASDAQ:VERO) up 82.8%.

Portfolio Pulse from Avi Kapoor

September 19, 2024 | 9:26 am

Darden Restaurants, Steelcase, FactSet Research, Exicure, and FedEx are key stocks to watch as they report earnings or receive significant updates. Darden and FactSet are expected to release earnings before the market opens, while FedEx will report after the closing bell. Steelcase reported better-than-expected earnings but missed sales estimates, and Exicure received a Nasdaq extension.

Portfolio Pulse from Avi Kapoor

September 19, 2024 | 6:30 am

Exicure Inc (NASDAQ:XCUR) shares soared in after-hours trading following an announcement of a Nasdaq listing extension. The company must comply with listing criteria by Nov. 14. Exicure recently regained compliance with Nasdaq's minimum bid price and converted $1 million of debt to equity. The stock, a low-float micro-cap, more than doubled, reaching new 52-week highs.

Portfolio Pulse from Adam Eckert

September 18, 2024 | 8:51 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.